Emergence of low-molecular-weight heparins in cardiology.
Drug therapy for the management of acute coronary syndromes is rapidly expanding. Over the past few years, a number of new antithrombotic agents have been introduced, including low-molecular-weight heparins. The epidemiology and pathophysiology of acute coronary syndromes are discussed, with a historical perspective on the use of antithrombotic therapy.
Stringer
K A
KA
Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA.
D000208:Acute Disease; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005544:Forecasting; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight